支持医保数据用于创新药研发！科创医药ETF嘉实(588700)上涨1.17%，近一周新增规模同类第一

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF, which has seen significant trading volume and asset growth, indicating investor interest in the sector [3] - As of June 30, the Kexin Pharmaceutical ETF has achieved a net value increase of 27.37% over the past year, with a maximum monthly return of 23.29% since inception [3] - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [3][5] Group 2 - Recent measures from the National Healthcare Security Administration and the National Health Commission support the use of medical insurance data for innovative drug development, enhancing collaboration among healthcare, insurance, and pharmaceutical sectors [5] - East China Securities emphasizes the importance of innovative drugs as a core investment theme, suggesting investors focus on companies with differentiated product offerings and strong potential for growth [6] - The global pharmaceutical investment landscape is recovering, positively impacting the CXO and upstream life sciences sectors, leading to improved order and financial performance [6]